This story has been updated with comments from a company earnings call.

NEW YORK (Genomeweb News) – Vermillion reported today that its second quarter revenues were $535,000, up 65 percent from $324,000 in Q2 2014 but falling short of the average Wall Street estimate of $1.2 million.

The company posted product revenue of $535,000, up 153 percent from $211,000 in Q2 2014. It had no license revenue, compared to $113,000 in the year-ago period.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

Sponsored by

This webinar will discuss an automated, high-throughput method of generating high-quality antigens and antibodies.